A Molecular Diagnostics Company
Making Early Cancer Detection the New Standard of Primary Care
For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.
Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.
More accurate & reliable
More cost effective
significant societal impact
Our Social Impact
ENMEDIA: Dx Companies On the Rise
October 16, 2023
AcuamarkDx is pleased to be featured as a diagnostics company on the rise in the premiere issue of ENMEDIA magazine.
Click the link below for the full story.
ENMEDIA Explores Podcast Liquid Biopsy: What’s next?
June 30, 2023
Dr. Giulia Kennedy and Dr. Bernard Peperstraete talk with ENMEDIA about AcuamarkDx's solution to crack early cancer detection – a potential game changer for the liquid biopsy market.
AcuamarkDx Welcomes Giulia Kennedy, PhD, to the Board of Directors
May 03, 2023
Dr. Kennedy brings more than two decades of experience developing novel diagnostic technologies, most recently served as global chief scientific officer and chief medical officer at Veracyte, a global diagnostics company.